KBC Group
AXSM icon

KBC Group’s Axsome Therapeutics AXSM Stock Holding History

KBC Group’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$189K Hold
1,121
– – ﹤0.01% 986
2025
Q4 		$205K Hold
1,121
– – ﹤0.01% 909
2025
Q3 		$136K Hold
1,121
– – ﹤0.01% 1089
2025
Q2 		$117K Sell
1,121
-299
-21% -$31.7K ﹤0.01% 1101
2025
Q1 		$166K Buy
1,420
+84
+6% +$9.57K ﹤0.01% 1171
2024
Q4 		$113K Buy
1,336
+385
+40% +$35.4K ﹤0.01% 1472
2024
Q3 		$85K Hold
951
– – ﹤0.01% 1389
2024
Q2 		$77K Hold
951
– – ﹤0.01% 1330
2024
Q1 		$76K Buy
951
+264
+38% +$22.2K ﹤0.01% 1276
2023
Q4 		$55K Sell
687
-109
-14% -$7.29K ﹤0.01% 1451
2023
Q3 		$56K Buy
+796
New +$59.5K ﹤0.01% 1345

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KBC Group's AXSM Position: Q1 2026 in Review

KBC Group held its Axsome Therapeutics (AXSM) position steady in Q1 2026 at 1,121 shares worth $189K. The position accounts for ﹤0.01% of the portfolio, ranked #986.

KBC Group first reported a position in AXSM in Q3 2023 and has held it in 11 quarters since. The position peaked at $205K in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • KBC Group held 1,121 shares of Axsome Therapeutics worth $189K as of Q1 2026.
  • KBC Group left its Axsome Therapeutics share count unchanged in Q1 2026.
  • Axsome Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #986 holding.
  • KBC Group first reported a position in Axsome Therapeutics in Q3 2023 and has held it in 11 quarters since.
  • KBC Group's Axsome Therapeutics position peaked at $205K in Q4 2025.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.